ArticleAnnals of the rheumatic diseases2016
Bortezomib in refractory ANCA-associated vasculitis: a new option?
Article in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.Clinical reviews in allergy & immunology · 2026Review
- BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis.Frontiers in immunology · 2026Review
- Investigating potential biomarkers associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis using Mendelian randomization and transcriptomic analysis.Arthritis research & therapy · 2025Article
- Review
- Drug repurposing for glomerular diseases: an underutilized resource.Nature reviews. Nephrology · 2024Review
- Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.Internal medicine (Tokyo, Japan) · 2024Article
- Clinical advances in immunotherapy for immune-mediated glomerular diseases.Clinical and experimental medicine · 2023Review
- Article
- Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.Frontiers in medicine · 2022Review
- B Lineage Cells in ANCA-Associated Vasculitis.International journal of molecular sciences · 2021Review
- Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies.Journal of translational autoimmunity · 2021Article
- Bortezomib in autoimmune hemolytic anemia and beyond.Therapeutic advances in hematology · 2021Review
- Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.BMC rheumatology · 2020Article
- The pathogenesis and treatment in antineutrophil cytoplasmic antibody associated vasculitis.American journal of translational research · 2020Review
- Review
- Pathogenesis and therapeutic interventions for ANCA-associated vasculitis.Nature reviews. Rheumatology · 2019Review
- Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.World journal of nephrology · 2018Review
- Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.Journal of the American Society of Nephrology : JASN · 2018Review
- Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.Therapeutic advances in neurological disorders · 2017Article
- Treatment of membranous nephropathy: time for a paradigm shift.Nature reviews. Nephrology · 2017Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.